These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

163 related articles for article (PubMed ID: 21568657)

  • 21. Stereotactically guided fractionated re-irradiation in recurrent glioblastoma multiforme.
    Combs SE; Gutwein S; Thilmann Ch; Huber P; Debus J; Schulz-Ertner D
    J Neurooncol; 2005 Sep; 74(2):167-71. PubMed ID: 16193388
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Can irradiation of potential cancer stem-cell niche in the subventricular zone influence survival in patients with newly diagnosed glioblastoma?
    Gupta T; Nair V; Paul SN; Kannan S; Moiyadi A; Epari S; Jalali R
    J Neurooncol; 2012 Aug; 109(1):195-203. PubMed ID: 22555992
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Phase II randomized trial of autologous formalin-fixed tumor vaccine for postsurgical recurrence of hepatocellular carcinoma.
    Kuang M; Peng BG; Lu MD; Liang LJ; Huang JF; He Q; Hua YP; Totsuka S; Liu SQ; Leong KW; Ohno T
    Clin Cancer Res; 2004 Mar; 10(5):1574-9. PubMed ID: 15014006
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Patterns of intracranial glioblastoma recurrence after aggressive surgical resection and adjuvant management: retrospective analysis of 43 cases.
    Konishi Y; Muragaki Y; Iseki H; Mitsuhashi N; Okada Y
    Neurol Med Chir (Tokyo); 2012; 52(8):577-86. PubMed ID: 22976141
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Human umbilical vein endothelial cell vaccine therapy in patients with recurrent glioblastoma.
    Tanaka M; Tsuno NH; Fujii T; Todo T; Saito N; Takahashi K
    Cancer Sci; 2013 Feb; 104(2):200-5. PubMed ID: 23106822
    [TBL] [Abstract][Full Text] [Related]  

  • 26. First results on survival from a large Phase 3 clinical trial of an autologous dendritic cell vaccine in newly diagnosed glioblastoma.
    Liau LM; Ashkan K; Tran DD; Campian JL; Trusheim JE; Cobbs CS; Heth JA; Salacz M; Taylor S; D'Andre SD; Iwamoto FM; Dropcho EJ; Moshel YA; Walter KA; Pillainayagam CP; Aiken R; Chaudhary R; Goldlust SA; Bota DA; Duic P; Grewal J; Elinzano H; Toms SA; Lillehei KO; Mikkelsen T; Walbert T; Abram SR; Brenner AJ; Brem S; Ewend MG; Khagi S; Portnow J; Kim LJ; Loudon WG; Thompson RC; Avigan DE; Fink KL; Geoffroy FJ; Lindhorst S; Lutzky J; Sloan AE; Schackert G; Krex D; Meisel HJ; Wu J; Davis RP; Duma C; Etame AB; Mathieu D; Kesari S; Piccioni D; Westphal M; Baskin DS; New PZ; Lacroix M; May SA; Pluard TJ; Tse V; Green RM; Villano JL; Pearlman M; Petrecca K; Schulder M; Taylor LP; Maida AE; Prins RM; Cloughesy TF; Mulholland P; Bosch ML
    J Transl Med; 2018 May; 16(1):142. PubMed ID: 29843811
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Phase 2 trial of radiation plus high-dose tamoxifen for glioblastoma multiforme: RTOG protocol BR-0021.
    Robins HI; Won M; Seiferheld WF; Schultz CJ; Choucair AK; Brachman DG; Demas WF; Mehta MP
    Neuro Oncol; 2006 Jan; 8(1):47-52. PubMed ID: 16443947
    [TBL] [Abstract][Full Text] [Related]  

  • 28. αvβ3 Integrin and Fibroblast growth factor receptor 1 (FGFR1): Prognostic factors in a phase I-II clinical trial associating continuous administration of Tipifarnib with radiotherapy for patients with newly diagnosed glioblastoma.
    Ducassou A; Uro-Coste E; Verrelle P; Filleron T; Benouaich-Amiel A; Lubrano V; Sol JC; Delisle MB; Favre G; Ken S; Laprie A; De Porre P; Toulas C; Poublanc M; Cohen-Jonathan Moyal E
    Eur J Cancer; 2013 Jun; 49(9):2161-9. PubMed ID: 23566417
    [TBL] [Abstract][Full Text] [Related]  

  • 29. DCVax®-L--developed by Northwest Biotherapeutics.
    Polyzoidis S; Ashkan K
    Hum Vaccin Immunother; 2014; 10(11):3139-45. PubMed ID: 25483653
    [TBL] [Abstract][Full Text] [Related]  

  • 30. First step results from a phase II study of a dendritic cell vaccine in glioblastoma patients (CombiG-vax).
    Ridolfi L; Gurrieri L; Riva N; Bulgarelli J; De Rosa F; Guidoboni M; Fausti V; Ranallo N; Calpona S; Tazzari M; Petrini M; Granato AM; Pancisi E; Foca F; Dall'Agata M; Bondi I; Amadori E; Cortesi P; Zani C; Ancarani V; Gamboni A; Polselli A; Pasini G; Bartolini D; Maimone G; Arpa D; Tosatto L
    Front Immunol; 2024; 15():1404861. PubMed ID: 39192978
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Preliminary results of active specific immunization with modified tumor cell vaccine in glioblastoma multiforme.
    Schneider T; Gerhards R; Kirches E; Firsching R
    J Neurooncol; 2001 May; 53(1):39-46. PubMed ID: 11678429
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Surgery, tamoxifen, carboplatin, and radiotherapy in the treatment of newly diagnosed glioblastoma patients.
    Puchner MJ; Herrmann HD; Berger J; Cristante L
    J Neurooncol; 2000 Sep; 49(2):147-55. PubMed ID: 11206010
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Heat-shock protein peptide complex-96 vaccination for recurrent glioblastoma: a phase II, single-arm trial.
    Bloch O; Crane CA; Fuks Y; Kaur R; Aghi MK; Berger MS; Butowski NA; Chang SM; Clarke JL; McDermott MW; Prados MD; Sloan AE; Bruce JN; Parsa AT
    Neuro Oncol; 2014 Jan; 16(2):274-9. PubMed ID: 24335700
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Autologous glioma cell vaccine admixed with interleukin-4 gene transfected fibroblasts in the treatment of patients with malignant gliomas.
    Okada H; Lieberman FS; Walter KA; Lunsford LD; Kondziolka DS; Bejjani GK; Hamilton RL; Torres-Trejo A; Kalinski P; Cai Q; Mabold JL; Edington HD; Butterfield LH; Whiteside TL; Potter DM; Schold SC; Pollack IF
    J Transl Med; 2007 Dec; 5():67. PubMed ID: 18093335
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Dendritic cell immunotherapy for glioblastoma.
    Polyzoidis S; Ashkan K
    Expert Rev Anticancer Ther; 2014 Jul; 14(7):761-3. PubMed ID: 24850137
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Efficacy and safety of intratumoral thermotherapy using magnetic iron-oxide nanoparticles combined with external beam radiotherapy on patients with recurrent glioblastoma multiforme.
    Maier-Hauff K; Ulrich F; Nestler D; Niehoff H; Wust P; Thiesen B; Orawa H; Budach V; Jordan A
    J Neurooncol; 2011 Jun; 103(2):317-24. PubMed ID: 20845061
    [TBL] [Abstract][Full Text] [Related]  

  • 37. A Cancer Research UK First Time in Human Phase I Trial of IMA950 (Novel Multipeptide Therapeutic Vaccine) in Patients with Newly Diagnosed Glioblastoma.
    Rampling R; Peoples S; Mulholland PJ; James A; Al-Salihi O; Twelves CJ; McBain C; Jefferies S; Jackson A; Stewart W; Lindner J; Kutscher S; Hilf N; McGuigan L; Peters J; Hill K; Schoor O; Singh-Jasuja H; Halford SE; Ritchie JW
    Clin Cancer Res; 2016 Oct; 22(19):4776-4785. PubMed ID: 27225692
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Phase 2 trial of copper depletion and penicillamine as antiangiogenesis therapy of glioblastoma.
    Brem S; Grossman SA; Carson KA; New P; Phuphanich S; Alavi JB; Mikkelsen T; Fisher JD;
    Neuro Oncol; 2005 Jul; 7(3):246-53. PubMed ID: 16053699
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Autologous adoptive immune-cell therapy elicited a durable response with enhanced immune reaction signatures in patients with recurrent glioblastoma: An open label, phase I/IIa trial.
    Lim J; Park Y; Ahn JW; Sim J; Kang SJ; Hwang S; Chun J; Choi H; Kim SH; Chun DH; Sung KS; Kwack K; Cho K
    PLoS One; 2021; 16(3):e0247293. PubMed ID: 33690665
    [TBL] [Abstract][Full Text] [Related]  

  • 40. A phase II study of conventional radiation therapy and thalidomide for supratentorial, newly-diagnosed glioblastoma (RTOG 9806).
    Alexander BM; Wang M; Yung WK; Fine HA; Donahue BA; Tremont IW; Richards RS; Kerlin KJ; Hartford AC; Curran WJ; Mehta MP
    J Neurooncol; 2013 Jan; 111(1):33-9. PubMed ID: 23086432
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.